Spyre Therapeutics Stock Five Year Return
| SYRE Stock | 27.00 0.50 1.82% |
Spyre Therapeutics fundamentals help investors to digest information that contributes to Spyre Therapeutics' financial success or failures. It also enables traders to predict the movement of Spyre Stock. The fundamental analysis module provides a way to measure Spyre Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Spyre Therapeutics stock.
Spyre | Five Year Return |
Spyre Therapeutics Company Five Year Return Analysis
Spyre Therapeutics' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Spyre Five Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Spyre Therapeutics is extremely important. It helps to project a fair market value of Spyre Stock properly, considering its historical fundamentals such as Five Year Return. Since Spyre Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spyre Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spyre Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
Spyre Return On Tangible Assets
Return On Tangible Assets |
|
According to the company disclosure, Spyre Therapeutics has a Five Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Spyre Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spyre Therapeutics' direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spyre Therapeutics could also be used in its relative valuation, which is a method of valuing Spyre Therapeutics by comparing valuation metrics of similar companies.Spyre Therapeutics is currently under evaluation in five year return category among its peers.
Spyre Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Spyre Therapeutics from analyzing Spyre Therapeutics' financial statements. These drivers represent accounts that assess Spyre Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Spyre Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 81.8M | 156.0M | 420.0M | 37.9M | 148.4M | 118.2M | |
| Enterprise Value | 69.0M | 133.5M | 335.4M | 7.7M | 44.1M | 77.9M |
Spyre Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Spyre Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Spyre Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Spyre Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 1.43 B | ||||
| Shares Outstanding | 58.71 M | ||||
| Shares Owned By Insiders | 8.80 % | ||||
| Shares Owned By Institutions | 88.30 % | ||||
| Number Of Shares Shorted | 8.25 M | ||||
| Price To Book | 9.24 X | ||||
| Price To Sales | 2,210 X | ||||
| Revenue | 886 K | ||||
| EBITDA | (242.3 M) | ||||
| Net Income | (338.79 M) | ||||
| Total Debt | 84.56 M | ||||
| Book Value Per Share | 3.34 X | ||||
| Cash Flow From Operations | (99.91 M) | ||||
| Short Ratio | 21.97 X | ||||
| Earnings Per Share | (37.90) X | ||||
| Target Price | 58.63 | ||||
| Number Of Employees | 30 | ||||
| Beta | 2.91 | ||||
| Market Capitalization | 1.59 B | ||||
| Total Asset | 341.86 M | ||||
| Retained Earnings | (764.41 M) | ||||
| Working Capital | 309.55 M | ||||
| Net Asset | 341.86 M |
About Spyre Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spyre Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spyre Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spyre Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out Spyre Therapeutics Piotroski F Score and Spyre Therapeutics Altman Z Score analysis. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.